Non-Covid-19 medical device approvals tick up alongside the agency’s pandemic efforts.
The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.
Aclaris takes a step towards an oral rheumatoid arthritis therapy.
Keytruda could soon be approved in periadjuvant breast cancer, but adjuvant lung cancer, a bigger setting, is 2021’s big showdown.
Aurinia’s only project is due in front of the FDA, and outcomes are expected for Merck KGaA, Bayer and Merck & Co.
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
The smaller company believes that its complement C3 inhibitor could make Soliris and Ultomiris redundant in PNH.
The nascent company hopes to prove that its inhaled pan-Jak is best in class.
Pinpointing new forms of the coronavirus could be vital, particularly if it mutates in response to vaccination, the company says.